MOR and COMT SNP Polymorphism and Pain
Does mu Opioid Receptor (MOR) and Catechol-O-methyltransferase (COMT) Genes Polymorphism Correlate of Clinical Postoperative Pain and Response to Analgesics
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Tallinn, Estonia, 11312
- Recruiting
- Yuri Kolesnikov MD PhD
-
Contact:
- Peeter Ross, MD
- Phone Number: 372 6973002
- Email: peeter.ross@itk.ee
-
Contact:
- Yuri Kolesnikov
- Phone Number: 372 6973002
- Email: yuri.kolesnikov@itk.ee
-
Sub-Investigator:
- Boris Gabovits, MD
-
Principal Investigator:
- Yuri Kolesnikov, MD PhD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- 18 years of age and older
- Give informed consent to participate in this study
Exclusion Criteria:
- Neurologic or psychiatric disease sufficient, in the clinical judgment of the investigator, to compromise informed consent or data collection
- ASA classification score 3 or above
- Patients with past or present history of substance abuse.
- Patients with a history of chronic pain requiring daily analgesic use for more then one month.
- Patients with a current diagnosis of anxiety or depression requiring medical treatment
- Patients allergic to morphine
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
dosing
|
Coded blood specimens will be transported to the Department of Gene Technology TTÜ and genotyping analysis will be performed.
Lymphocytes will be isolated from blood specimens using Ficol-Paq gradients, and genomic DNA isolated using a salting-out procedure.
Variants of the MOR gene and other genes of interests will be performed by DNA sequence analysis of PCR-amplified DNA, using primers located in flanking intron sequence.
All methods proposed are currently in operation in the respective facilities.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Postoperative assessments include PCA use (e.g., number of patient demands, total morphine administered) in each 24-h interval during the 48-h study period - primary endpoint.
Time Frame: 48 hours
|
48 hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
No secondary outcome endpoint
Time Frame: no time frame
|
no time frame
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Yuri Kolesnikov, MD PhD, ETCH
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
Other Study ID Numbers
- ITK-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.